About
Experience
Proven track record of collaborating with cross-functional and cross-geography partners within biopharma organizations of various sizes to successfully achieve set goals and beyond
Core Capabilities by Project Type
Commercialization and Brand Strategy
Development of commercial strategy, market positioning, and globally-aligned message platforms
Synthesis of market insights and implications
Long-range planning
Commercial evaluations
Launch Planning and Execution
Development and execution of plans for first-in-market and LCM indications, including:
Cross-functional launch readiness frameworks
Launch readiness reviews
Pre-launch and launch commercialization plans
Annual Global / US Brand Planning
Cross-functional budget planning / prioritization for strategies and tactics
Therapeutic Area Assessment and Strategy
Summary of available clinical data
Evaluation of competitors and pipeline
Synthesis of current and future scientific, clinical, and market access trends
Development of strategic implications
Competitive Intelligence and Planning
Synthesis of competitor data, product attributes, and strategy
Execution of competitive simulation workshops
Development of counter-messages and strategies / tactics
Scenario planning
Cross-functional Planning and Execution
Leadership of cross-functional senior stakeholders in planning and executing against major milestones, including:
New data sets / indications
Changes to packaging, formulation, and USPI
Market Research
Evaluation of:
Market segmentation
Future clinical / market access trends in disease management
Target product profiles
Promotional messages / materials
Brand perceptions / performance
KOL / KEE Engagement and Collaboration
Moderation of ad boards
Training of promotional speakers
Market research and consultation
Collaboration on peer-to-peer marketing initiatives
Financial Planning & Analysis
OPEX / SG&A forecasting and budget (up to $100 MM) optimization
Consultation on revenue model structure and assumptions
Evaluation of KPIs
Senior Leadership Engagement and Governance
Creation of key strategic presentations, including:
Brand performance reviews
Board of Directors briefings
Launch readiness reviews
Facilitation of meetings and decision-making
Brand Marketing and Management
Development of claims, sales pieces, and digital / peer-to-peer assets
MLR review
GPO and congress strategy / execution
Media planning and performance evaluation
Vendor management
Field Force Training and Engagement
Facilitation of workshops and creation of training resources on:
Disease state
Competitors and landscape product data
Strategy
Messaging
Promotional materials
Call flows
Therapeutic Area
Experience
+ Oncology
- Facilitated discussion and decision-making with biopharma C-Suite Executives and Commercial Leadership around solid tumor market growth initiatives and competitor response strategy for major LCM indication approval
- Informed global clinical development strategy for novel oral oncolytic in CLL and FL based on US and EU5 payer and KOL research
- Augmented launch preparation activities for solid tumor brand, including competitive planning, field force training, and development of commercial strategy, messaging platform, and US Launch Plan
- Synthesized market insights and facilitated cross-functional alignment, prioritization, and action planning for solid tumor brand
- Informed pre-launch competitive planning and scientific platform development for novel oral oncolytic in CLL / FL
- Led commercial collaboration with diagnostic partner to prepare for Dx-linked LCM launch for solid tumor brand, ultimately driving double-digit quarter-over-quarter sales growth
- Analyzed published data to conduct evaluation of of ~800 clinical-stage oncology assets across 30 solid and hematologic tumor types and prioritized BD opportunities for a large pharma client
+ Rare Disease
- Developed launch preparation framework and assessed key drivers and barriers for novel RNAi therapeutic targeting rare, hereditary, progressive neurological disorder
- Created orphan drug database and Excel-based tool to model US, EU5, and JPN pricing corridors for future rare disease drugs based on disease and product attributes
- Identified opportunities to differentiate product candidate for rare hematologic disorder by addressing patient and payer service and educational needs
- Characterized diagnostic pathway, identified leakage points, and developed strategies to improve patient diagnosis and treatment rates for rare cardiovascular disease
+ Immunology
- Conducted therapeutic area assessment for global inflammatory bowel disease franchise, including evaluation of BD opportunities and emerging science of novel biomarkers
- Facilitated live workshop for global inflammatory bowel disease franchise to define and prioritize near- and long-term growth opportunities
- Developed recommendations for phase 3 clinical trial design of investigational inflammatory bowel disease drug based on understanding of current and future clinical and market access dynamics
- Informed valuation of novel drug candidate addressing food allergies
What Industry Leaders Are Saying
“Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.”
- Quote Source (optional)